Primary Tumour Volume: Important Predictor of Outcome for T3- and T4-Staged Nasopharyngeal Carcinoma

2004 ◽  
Vol 33 (04) ◽  
pp. 254 ◽  
Author(s):  
Mu-Kuan Chen ◽  
Hong-Shen Lee ◽  
Cheng-Chuan Chang
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Primary Tumour ◽  
Tumour Volume ◽  
Important Predictor

Primary Tumour Volume Delineation in Nasopharyngeal Carcinoma and Correlation with 1997 AJCC Tumour Stage Classification

2001 ◽  
Vol 30 (04) ◽  
pp. 231 ◽  
Author(s):  
Cheng-Chuan Chang ◽  
Mu-Kuan Chen ◽  
Mu-Tai Liu ◽  
Yung-Sung Wen ◽  
Hwa-Koon Wu ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Primary Tumour ◽  
Tumour Volume ◽  
Tumour Stage ◽  
Volume Delineation ◽  
Stage Classification

scholarly journals Prognostic significance of primary tumour volume in nasopharyngeal carcinoma – a single institute study

2019 ◽  
Vol 7 (1) ◽  
pp. 24-29
Author(s):  
Dr. S.D. Shamsundar ◽  
◽  
Dr. Jagannath K.P. ◽  
Dr. Niveditha S. ◽  
Dr. K. Aradhana ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Primary Tumour ◽  
Prognostic Significance ◽  
Tumour Volume

Expression of p53 Protein and Primary Tumour Volume in Patients with Nasopharyngeal Carcinoma

2004 ◽  
Vol 33 (05) ◽  
pp. 304 ◽  
Author(s):  
Mu-Kuan Chen ◽  
Hong-Shen Lee ◽  
Julia H. Chang ◽  
Cheng-Chuan Chang
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
P53 Protein ◽  
Primary Tumour ◽  
Tumour Volume

scholarly journals Early intra-treatment diffusion weighted magnetic resonance imaging in patients with recurrent nasopharyngeal carcinoma treated with nivolumab

2020 ◽  
Vol 6 (3) ◽  
pp. 568
Author(s):  
Tiffany Y. So ◽  
Qi-Yong Ai ◽  
Brigette B.Y. Ma ◽  
Ann D. King
Keyword(s):  
Magnetic Resonance Imaging ◽  
Overall Survival ◽  
Magnetic Resonance ◽  
Nasopharyngeal Carcinoma ◽  
Progression Free Survival ◽  
Tumour Volume ◽  
Resonance Imaging ◽  
Free Survival ◽  
Diffusion Weighted ◽  
Weighted Magnetic Resonance Imaging

<p class="abstract">Immune check point inhibitors have demonstrated promising efficacy in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) in phase I and phase II trials. Early identification of treatment response is important in these patients. This report aimed to document the early intratreatment diffusion weighted magnetic resonance imaging (DW-MRI) findings in NPC patients following treatment with the programmed cell death-1 inhibitor, nivolumab. Two consecutive patients with histologically confirmed recurrent undifferentiated NPC treated with nivolumab were prospectively recruited. Nivolumab was administered at a dosage of 3 mg/kg intravenously every 2 weeks. Patients underwent magnetic resonance imaging examinations at baseline, and at 3 and 5 weeks after commencement of treatment. Intratreatment changes in tumour volume and apparent diffusion coefficient (ADC<sub>mean</sub>)were calculated. The endpoints were objective response by response evaluation criteria in solid tumors and survival. In patient 1, an intratreatment ADC increase at 5 weeks corresponded with anatomical tumour volume reduction and a better long-term survival outcome (progression free survival 1.3 years, overall survival 2.9 years). In patient 2, an intratreatment ADC decrease at 5 weeks corresponded to progressive disease and worse outcome (progression free survival 0.0 years, overall survival 0.9 years). Intratreatment ADC changes at 3 weeks were not associated with response outcome. These cases suggest that intratreatment changes in ADC at 5 weeks may potentially predict tumour response in patients treated with nivolumab. Dedicated studies are needed to clarify these findings and fully characterise patterns of treatment related ADC change.</p>

Two or four hour [18F]FMISO-PET in HNSCC

2011 ◽  
Vol 50 (01) ◽  
pp. 22-27 ◽  
Author(s):  
R. Haase ◽  
A. Koch ◽  
D. Zips ◽  
J. Steinbach ◽  
M. Baumann ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Signal To Noise Ratio ◽  
Primary Tumour ◽  
Prospective Trial ◽  
Tumour Volume ◽  
Test Results ◽  
Non Invasive ◽  
Positron Emission ◽  
Static Images ◽  
The Mean

Summary[18F]Fluoromisonidazole positron emission tomography (FMISO-PET) is a non invasive imaging technique that can assist detecting intra tumour regions of hypoxia. FMISO-PET evinces comparatively low signal-to-noise-ratio (SNR) and may be acquired dynamically or after different uptake times post injection (p. i.). The aim of this study was to identify, if static images acquired two hours (MISO2) or four hours (MISO4) p. i. reveal higher contrast. Patients, methods: As part of a prospective trial, 23 patients with cancers of the head and neck underwent [18F]fluoro deoxyglucose (FDG) PET before and during curative radiochemotherapy. Additionally, FMISO-PET studies 2 h and 4 h p. i. were done before treatment and after a mean dose of 11 Gy, 23 Gy and 57 Gy during RCT. After coregistration, a dedicated software was used to define the gross tumour volume (GTV) by FDG PET for the primary tumour. This volume was overlaid to the FMISO images and hypoxia within the GTV was determined. The contrast between hypoxia determined by MISO2 and by MISO4 was investigated and analysed with the Wilcoxon-matched-pairs test. Results: Mean SUVmax in tumours of all examinations was 2.2 (stdev: 0.4, min: 1.3, max: 3.4) after 2 h and 2.4 (stdev: 0.7, min: 1.1, max: 4.4) after 4 h. In the neck musculature the mean SUVmax was 1.5 at both time points and the mean SUVmean decreased from 1.2 after 2 h to 1.1 after 4 h, respectively. These effects resulted in significantly rising contrast ratios from MISO2 to MISO4. The differently defined contrasts revealed significantly higher values for examinations 4 h p. i. (p < 0.002). Conclusion: Data acquisition of [18F]FMISO should be done 4 h p. i. to gather the optimal contrast, preferably allowing further analysis, e. g. hypoxic sub volume definition for therapy planning.

Multivariate analysis based risk grouping of ewing tumours (ET) with extra-pulmonary metastatic disease (EPMD): Final results from the Euro Ewing 99 study

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 9562-9562
Author(s):  
R. Ladenstein ◽  
J. Whelan ◽  
O. Oberlin ◽  
C. Weston ◽  
H. Jürgens
Keyword(s):  
Multivariate Analysis ◽  
Primary Tumour ◽  
Local Treatment ◽  
Risk Groups ◽  
Tumour Volume ◽  
Bone Lesions ◽  
Free Survival ◽  
Ewing Tumours ◽  
Single Bone

9562 Background: To identify an effective treatment for patients with EPMD. Methods: 192 patients (pts) were registered. Median age is 15.8 years (yrs) (0.4–49.29). Primary site was extremity in 57 pts and axial/other in 135 pts (40.6% in the pelvis). Tumour volume was ≥ 200 ml in 114pts. Metastatic spread was bone marrow (BM) only in 19 pts, bone only in 93 pts and bone and BM in 79 pts. Six VIDE induction cycles were completed by 168 pts (85%). Local treatment included surgery when possible and/or radiotherapy (Rx) as indicated. Recommended HDT was busulphan (BU) 600 mg/m2 and melphalan (MEL) 140 mg/m2 with PSCR. Median follow up is 4.2 years (range: 1.9–6.6). Results: Partial remission or better was achieved after cycle 6 in 75/116 pts subjected to HDT/SCR (65%). The overall survival at 3 years for all 192 pts is 29% (95% CI=0.04). Significantly favourable univariate factors in the unselected cohort at diagnosis (Dx) were age < 14 yrs (event free survival at 3 yrs (EFS) 37%, p=0.006), BM involvement only (EFS 47%, p=0.024), single bone lesions only (EFS 35%, p=0.009), extremities (EFS 34%, p=0.007) and tumour volume of <200 ml (EFS 47%, p<0.001). For pts receiving BuMel it is noteworthy that 37 pts of <14a and EPMD achieved an EFS of 47% in comparison to older counterparts >14a (EFS 22% (p=0.026). Multivariate analysis identified two major risk factors at Dx: primary tumour volume >200 ml p<0.001 (RR 2.25) and > 5 bone metastases p=0.064 (RR 2.11). In these risk groups the 3 yr EFS was 56% for 35 pts with <200 ml and <5 bone lesions, for 17pts with <200 ml > 5 bone lesions 29%, for 67 pts >200 ml or < 5 bone lesions 19% and extremely dismal for 47 pts with >200 ml and > 5 bone lesions with 7% (p<0.001). Conclusions: Groups with differing prognoses from EPMD have been identified from this prospectively followed cohort. Aggressive treatment with HDT appears effective only for sub groups of patients with EPMD and ET. No significant financial relationships to disclose.

Effect of Primary Tumour Volumes in Early T-Stage Nasopharyngeal Carcinoma

2003 ◽  
Vol 32 (02) ◽  
pp. 87 ◽  
Author(s):  
Cheng-Chuan Chang ◽  
Mu-Kuan Chen ◽  
Mu-Tai Liu ◽  
Hwa-Koon Wu ◽  
Kai-Lin Hwang
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Primary Tumour ◽  
T Stage

Metabolic Activity Via 18 F-FDG PET/CT is Predictive of Microsatellite Instability Status In Colorectal Cancer

2021 ◽  
Author(s):  
Jinling Song ◽  
Maomao Wei ◽  
Xuejuan Wang
Keyword(s):  
Colorectal Cancer ◽  
Microsatellite Instability ◽  
Primary Tumour ◽  
Tumour Volume ◽  
Total Lesion Glycolysis ◽  
Metabolic Tumour Volume ◽  
Metabolic Characteristics ◽  
Positron Emission ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Purpose: Identification of microsatellite instability high (MSI-H) colorectal cancer (CRC) is crucial for screening patients most likely to benefit from immunotherapy. We aim to investigate whether the metabolic characteristics is related to MSI status and can be used to predict the MSI-H CRC. Methods: A retrospective analysis was conducted on 420 CRC patients who were identified via [18F]fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography(CT) prior to therapy. Maximum standardised uptake (SUVmax), mean standardised uptake (SUVmean), metabolic tumour volume (MTV) and total lesion glycolysis (TLG) of the primary tumour were calculated and compared between MSI-H and microsatellite stability (MSS). Predictive factors of MSI status were selected from metabolic parameters and clinicopathological profiles via a multivariate analysis.Results: Of 420 colorectal cancers, 44 exhibited a high incidence of MSI. Both MTV and TLG were significantly higher in MSI-H group compared with the MSS group (P=0.004 and P=0.010, respectively). Logistic regression analysis indicated that CRC with MSI-H were related to younger age (P=0.013), primary lesion located at right hemi-colon (P<0.001) and larger MTV on PET/CT imaging (P=0.019). MTV more than 32.19 cm3 of colorectal cancer was linked to the presence of MSI (P=0.019). Conclusion: Tumor metabolic burden were higher in MSI-H CRC which may be useful for predicting the MSI status of CRC patient and thus aid in determination of immunotherapy for patients with CRC.

Sign in / Sign up

Export Citation Format

Share Document